Overview: B Cell Chimerism TestIntroduction: The B Cell Chimerism Test analyzes B cell chimerism to monitor bone marrow transplant success, ensuring proper engraftment. Aligned with 2023 AST guidelines, it uses PCR for high specificity, aiding in transplant screening. This test is critical for guiding post-transplant management, monitoring engraftment, and improving outcomes in molecular pathology for transplant patients.
Other Names: Chimerism B Cell Assay, Transplant Monitoring Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Chimerism testing began in the 1990s with transplant research. PCR-based B cell assays emerged in the 2000s, improving engraftment monitoring.
Purpose: Monitors bone marrow transplant success, guides immunosuppression, and assesses B cell chimerism in transplant patients.
Test Parameters: 1. Chimerism B Cell (CD19)
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva at any time. Report transplant history or symptoms like graft failure, and list medications like immunosuppressants.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL bone marrow (EDTA), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document transplant history, graft-versus-host disease, or immunosuppression status. Include current medications, especially cyclosporine or tacrolimus.
Consent: Written consent required, detailing the tests purpose, implications for transplant monitoring, and potential need for immunosuppression adjustments.
Procedural Considerations: Uses PCR to analyze B cell chimerism (CD19). Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low sample quality or improper storage can reduce sensitivity. Contamination may cause false results.
Clinical Significance: Mixed or donor chimerism confirms engraftment success, guiding immunosuppression. Recipient chimerism may indicate graft failure, prompting intervention.
Specialist Consultation: Consult a hematologist for result interpretation. A transplant specialist referral is advised for graft failure concerns.
Additional Supporting Tests: T cell chimerism test, bone marrow biopsy, or flow cytometry to assess transplant status.
Test Limitations: False results may occur with low cell counts. Results require clinical correlation with transplant history.
References: AST Transplant Guidelines, 2023; Biology of Blood and Marrow Transplantation, Antin JH, 2022.
